Novel potent activin antagonist

First-in-class activin antagonist, specifically binding to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members

Nucleosidic antibiotic

Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD

Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition

Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity

Novel modulator of the NusB-NusE interaction

p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent

Potent and selective p53-MDM2 binding inhibitor

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel phosphodiesterase 4D (PDE4D) inhibitor

Novel Inhibitor of the Cysteine Protease Cathepsin K

Novel potent and selective antagonist of somatostatin receptor subtype SST(3)

Novel BCR-ABL Kinase Inhibitor

Novel dual inhibitor of TORC1 and TORC2

Novel potent Jak2 type 1 inhibitor

Novel potent and selective p53-HDM2 inhibitor